{"@id":"https://bioecon.ru/technology/semaglutide-biosimilars/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/semaglutide-biosimilars/","json":"https://en.bioecon.ru/api/v1/technology/semaglutide-biosimilars/index.json"},"id":"semaglutide-biosimilars","industries":["pharma","biomanufacturing","longevity"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/","https://bioecon.ru/industries/longevity/"],"suppliers":["https://bioecon.ru/companies/orf-genetics/","https://bioecon.ru/companies/zero-cow-factory/","https://bioecon.ru/companies/loopworm/","https://bioecon.ru/companies/jiangsu-jland-biotech/","https://bioecon.ru/companies/dyadic-international/","https://bioecon.ru/companies/jiangsu-trautec/","https://bioecon.ru/companies/spiber-technologies-ab/","https://bioecon.ru/companies/giant-biogene-holding/","https://bioecon.ru/companies/isomerase/","https://bioecon.ru/companies/ecogreen-oleochemicals/"]},"maturity":8,"name":"Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)","regions":["us","cn","eu"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-15","entity":"sciencedirect.com","kind":"research","urls":["https://doi.org/10.1016/j.peptides.2021.170624"]},{"date":"2026-11-15","entity":"ema.europa.eu","kind":"official","urls":["https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic"]}],"stages":[{"n":1,"title":null},{"n":2,"title":null},{"n":3,"title":null},{"n":4,"title":null},{"n":5,"title":null}],"summary":"Industrial manufacturing of recombinant semaglutide GLP-1 receptor agonists combining high-density fed-batch fermentation of Pichia pastoris or E. coli with enzymatic leader cleavage and selective Lys26 acylation with a mono-fatty diacid hydrophilic spacer.","url":"/technology/semaglutide-biosimilars/","verified":"2026-11-15"}